• Dandan Xia, Huiyu Wang, Runjie Wang, Chaoying Liu, and Junying Xu.
• Department of Oncology, Wuxi People's Hospital, Wuxi, P.R. China.
• Medicine (Baltimore). 2018 Jun 1; 97 (24): e11115.

RationaleEndocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice.Patient ConcernsWe present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure.DiagnosesThe patient was rarely diagnosed breast cancer metastasis to the kidney and a positive hormone status (ER and PR) but was negative for human epidermal factor receptor 2 (HER2).InterventionsThe patient was treated with a high dose of fulvestrant (SERD; 500 mg) by intramuscular injection once per month.OutcomesThe patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including dry cough and blood phlegm also improved.LessonsEndocrinotherapy with high-dose fulvestrant may provide benefits for patients with HR+/HER2- advanced breast cancer with renal metastasis after SERMs failure.

26 keywords...

hide…